Table 1 Baseline characteristics of total study subjects
From: Impact of Pneumocystis jirovecii pneumonia on kidney transplant outcome
Variables | Total (n = 1502) | PCP negative (n = 1434) | PCP positive (n = 68) | P |
|---|---|---|---|---|
Age (years) | 45.3 ± 13.0 | 45.1 ± 13.0 | 48.3 ± 14.4 | 0.053 |
Female (%) | 39.1 | 39.9 | 23.5 | 0.007 |
Body mass index (kg/m2) | 22.5 ± 3.7 | 22.5 ± 3.8 | 22.6 ± 2.6 | 0.969 |
Donor type (%) | 0.124 | |||
Living | 67.4 | 67.8 | 58.8 | |
Deceased | 32.6 | 32.2 | 41.2 | 0.391 |
Standard criteria donor | 25.4 | 25.2 | 29.4 | |
Expanded criteria donor | 7.2 | 7.0 | 11.8 | |
Pre-transplant dialysis (%) | 0.005 | |||
Preemptive | 15.6 | 15.3 | 22.1 | |
Hemodialysis | 65.2 | 66.0 | 47.1 | |
Peritoneal dialysis | 19.2 | 18.7 | 30.9 | |
Duration of dialysis (months) | 40.1 ± 47.7 | 40.0 ± 47.5 | 42.9 ± 51.9 | 0.650 |
Re-transplantation | 7.2 | 7.2 | 7.4 | 0.958 |
ABO-incompatible (%) | 7.4 | 6.8 | 19.1 | < 0.001 |
HLA mismatch (numbers) | 3.1 ± 1.7 | 3.1 ± 1.7 | 3.1 ± 1.7 | 0.983 |
HLA-A | 0.9 ± 0.7 | 0.9 ± 0.7 | 1.0 ± 0.8 | 0.344 |
HLA-B | 1.2 ± 0.7 | 1.2 ± 0.7 | 1.2 ± 0.8 | 0.861 |
HLA-DR | 1.0 ± 0.7 | 1.0 ± 0.7 | 0.9 ± 0.7 | 0.291 |
Calcineurin inhibitor (%) | 0.260 | |||
None | 3.1 | 3.0 | 5.9 | |
Cyclosporine | 13.0 | 13.2 | 8.8 | |
Tacrolimus | 83.9 | 83.8 | 85.3 | |
mTOR inhibitor (%) | 1.9 | 1.9 | 2.9 | 0.535 |
Induction regimen (%) | 0.022 | |||
None | 19.0 | 19.6 | 7.4 | |
Basliximab | 79.6 | 78.9 | 92.6 | |
Antithymocyte globulin | 1.4 | 1.5 | 0 | |
Desensitization (%) | 11.5 | 10.9 | 22.1 | 0.005 |
Diabetes mellitus (%) | 19.0 | 18.9 | 22.1 | 0.517 |
Hypertension (%) | 89.9 | 89.5 | 98.5 | 0.016 |
DMN for kidney failure (%) | 16.4 | 16.3 | 19.1 | 0.543 |
Positivity for CMV (%) | 21.4 | 19.5 | 60.3 | < 0.001 |
Oral prophylactic antibiotics (%) | 18.8 | 19.2 | 10.3 | 0.067 |